[ET Net News Agency, 22 June 2020] Hansoh Pharmaceutical Group Company Limited (03692)
said "Olanzapine Orally Disintegrating Tablets", developed by Jiangsu Hansoh
Pharmaceutical Group Co., Ltd., a subsidiary of the Company, has been granted drug
registration approval by the National Medical Products Administration of the People's
Republic of China.
The product is an atypical antipsychotic agent indicated for (1) treatment of
schizophrenia; (2) maintenance treatment for patients with effective initial treatment of
olanzapine, which can effectively maintain improvement in clinical symptoms; (3) treatment
of moderate-to-severe manic episode; and (4) recurrence prevention of bipolar disorder for
manic episodes with effective initial treatment of olanzapine. (RC)